Vladimir Maletic
Greer, SCNPI 1336217801
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,893,625 of the $2,581,905 with a category attached, or 73.3%. 25 manufacturers reported payments, led by AbbVie at 31.0% of the total.
Across 2,311 payments — averaging $1117.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$801K
- Otsuka America Pharmaceutical, Inc.$458K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$353K
- Johnson & Johnson$226K
- Supernus Pharmaceuticals, Inc.$163K
- Axsome Therapeutics, Inc.$130K
- plus $450K from 19 others
What the payments were for
- Consulting fees$292,34711%
- Speaking & faculty fees$1,893,62573%
- Travel & lodging$353,87814%
- Food & beverage$42,0552%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 726 | $801,492 |
| Otsuka America Pharmaceutical, Inc. | 495 | $458,365 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 283 | $352,779 |
| Johnson & Johnson | 197 | $225,883 |
| Supernus Pharmaceuticals, Inc. | 161 | $162,611 |
| Axsome Therapeutics, Inc. | 112 | $130,398 |
| Sunovion Pharmaceuticals Inc. | 106 | $114,445 |
| Alkermes, Inc. | 69 | $97,131 |
| H. Lundbeck A S | 16 | $69,155 |
| E.r. Squibb & Sons, L.L.C. | 21 | $23,070 |
| Janssen Scientific Affairs, LLC | 11 | $18,169 |
| Alfasigma USA, Inc. | 7 | $17,355 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 7 | $16,040 |
| Eisai Inc. | 22 | $15,256 |
| Sage Therapeutics, LLC | 16 | $14,597 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $11,577 |
| Boehringer Ingelheim | 9 | $9,744 |
| Sumitomo Pharma America, Inc. | 1 | $9,280 |
| Neurelis, Inc. | 11 | $8,045 |
| Janssen Global Services, LLC | 7 | $7,532 |
| Livanova USA, Inc. | 3 | $6,151 |
| Corium, LLC | 3 | $4,578 |
| Noven Pharmaceuticals, Inc. | 1 | $4,248 |
| Ironshore Pharmaceuticals Inc. | 14 | $3,685 |
| Neurocrine Biosciences, Inc. | 4 | $320 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$784,565
- REXULTI$488,920
- CAPLYTA$349,766
- LYBALVI$294,123
- SPRAVATO$238,936
- Auvelity$129,486
- LATUDA$108,649
- QELBREE$95,544
- BRINTELLIX$29,330
- COBENFY$21,982
- TRINTELLIX$11,493
- Dayvigo$10,162
- VNS Therapy Symmetry Model 8103 Generator$6,151
- QULIPTA$6,000
- Azstarys$4,578
- Jornay PM 20mg capsules (Bottle of 100)$3,333
- ARISTADA$906
- VALTOCO$372
- ARISTADA INITIO$122
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 12 | $28,296 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $16,563 |
| Lisdexamfetamine Dimesylate | 16 | $4,239 |
| MydayisDextroamphetamine/Amphetamine | 11 | $3,630 |
| Bupropion XlBupropion Hcl | 30 | $945 |
| Lamotrigine | 49 | $866 |
| Aripiprazole | 24 | $718 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 31 | $614 |
| Escitalopram Oxalate | 28 | $512 |
| Bupropion Hcl SrBupropion Hcl | 21 | $431 |
| Quetiapine Fumarate | 26 | $413 |
| Duloxetine Hcl | 16 | $361 |
| Alprazolam | 47 | $121 |
| Zolpidem Tartrate | 24 | $94 |
| Fluoxetine Hcl | 19 | $83 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $458,365 | $28,29612 claims |
| Axsome Therapeutics, Inc.Auvelity | $130,398 | $16,56312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in South Carolinaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.